NB
Therapeutic Areas
Altis Biosystems Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RepliGut® Planar Model Kits | Pre-clinical Drug Discovery Tool | Commercial Tool |
| RepliGut® Services | Contract Research for Drug Discovery | Service Offering |
| RepliGut® for GI Toxicity Screening | Prediction of Drug-Induced Gastrointestinal Toxicity | Pre-clinical Tool |
| RepliGut® for Intestinal Barrier Function | Assessment of Gut Barrier Integrity | Pre-clinical Tool |
| RepliGut® for Inflammatory Response | Modeling Inflammatory Bowel Disease (IBD) / Inflammation | Pre-clinical Tool |
| RepliGut® for Drug Disposition (DMPK) | Prediction of Oral Drug Absorption & Bioavailability | Pre-clinical Tool |
| RepliGut® for Gut-Brain Axis / GLP-1 Research | Modeling Gut Hormone Release (e.g., GLP-1) & Signaling | Pre-clinical Tool |
Leadership Team at Altis Biosystems
BS
Ben Scruggs, Ph.D.
Chief Executive Officer
MB
Maureen Bunger, Ph.D, M.B.A.
Senior Director of Commercial Strategy
EB
Elizabeth Boazak, PhD
Director of Research & Development
BM
Bryan McQueen, PhD
Senior Scientist II, Manager of Commercial Operations
SP
Swetha Peddibhotla, PhD
Senior Scientist
ET
Earnest Taylor, PhD
Research Scientist II
SB
Stephanie Buchko-Beam
Senior HR Manager
MS
Melanie Sawyer
Senior QA Specialist I
LD
Lauren Di Lella
Senior Research Associate
MC
Mariana Castillo
Senior QA Associate